The FDA has approved Bavencio® (avelumab; EMD Serono) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Genome-wide association studies have revealed over 180 SNPs associated with increased breast cancer risk.
A team of investigators from the University of Texas MD Anderson Cancer Center assessed whether a relationship exists between hepatitis C virus infection and common genitourinary cancers, such as kidney and prostate cancer.
The new guidance aims to support urologists and other clinicians in providing evidence-based care to their patients.
Adding avelumab to best supportive care following chemo in advanced UC significantly improved OS compared with best supportive care alone.
After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
Height inversely linked to bladder cancer, while excess BMI gain in childhood linked to increased risk.
In a phase 3 trial, atezolizumab plus platinum-based chemotherapy as first-line treatment for metastatic urothelial carcinoma improved progression-free survival vs chemotherapy alone.